secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-05-15T11:07:13+00:00
Accession:  0001104659-26-061773
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel reports Q1 net loss $12.7M; FDA sets Nov 14 PDUFA for at-home IGALMI
----------------------------------------------------------------------------

- FDA accepted sNDA for IGALMI at-home use in agitation associated with bipolar/schizophrenia; PDUFA date Nov 14, 2026.
- Net revenue $206K (up 23% YoY from $168K); net loss $12.7M vs $7.3M in Q1 2025.
- Engaged MTS Health Partners to explore strategic options including sale, merger, or collaboration.
- Cash and equivalents $17.2M as of Mar 31, 2026; company in compliance with credit covenants.
- R&D down to $3.0M from $4.6M due to SERENITY trial completion; SG&A up to $7.2M from $5.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/0001104659-26-061773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-061773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer